Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P372: Neurological symptoms and imaging abnormalities in brain MRI in patients with Crohn’s disease receiving anti-TNFa therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Papatheodoridi*1, A. Euthumiou2, N. Perlepe3, F. Gagas3, M. Gizis3, S. Lagou3, G. Kounadis3, J. Koutsounas3, G. Bamias3

1GI Unit, 3rd Academic Department of Internal Medicine, Athens, Greece, 2General Hospital ‘Laikon’, Neurological Unit,, Athens, Greece, 3Sotiria Hospital, National and Kapodistrian University of Athens, GI-Unit, 3rd Academic Department of Internal Medicine, Athens, Greece

P373: Effect of risankizumab on improved and sustained quality of life in patients with moderate to severe Crohn’s disease: Phase 2 trial results

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Louis*1, W. J. Sandborn2, G. D’Haens3, F. Baert4, J. Kalabic5, K. Wallace6, W-J. Lee6, B. G. Feagan7

1University Hospital CHU of Liège, Liège, Belgium, 2University of California San Diego, La Jolla, USA, 3Academic Medical Center, Amsterdam, The Netherlands, 4AZ Delta Roeselare-Menen, Menen, Belgium, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 6AbbVie Inc., North Chicago, USA, 7University of Western Ontario, Robarts Research Institute, London, Canada

P374: Effects of subcutaneous vedolizumab on health-related quality of life and work productivity in patients with ulcerative colitis: results from the Phase 3 VISIBLE 1 trial

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Vermeire1, Ž. Krznarić2, T. Kobayashi3, J. Chen4, C. Agboton5, K. Kisfalvi4, H. Patel*6, W. Sandborn7

1University Hospitals Leuven, Leuven, Belgium, 2University Hospital Centre Zagreb, Zagreb, Croatia, 3Kitasato University Kitasato Institute Hospital, Tokyo, Japan, 4Takeda Development Center Americas Inc., Cambridge, USA, 5Takeda Pharmaceuticals International AG, Zurich, Switzerland, 6Takeda Pharmaceuticals International, Deerfield, USA, 7University of California - San Diego, La Jolla, USA

P375: Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multi-centre case series

ECCO '19 Copenhagen

Year: 2019
Authors:

F. M. Phillips*1, B. Verstockt2,3, S. Sebastian4,5, D. G. Ribaldone6, S. Vavricka7, K. Konstantinos8, E. Slattery9, N. de Suray10,11, C. Flores12, W. Fries13, F. Vincenzi14, E. Capoferro15, O. Bachmann16, U. Kopylov17, ECCO CONFER Investigators1

1St Mark's Hospital, Inflammatory Bowel Disease, London, UK, 2University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, 4Hull and East Yorkshire Hospitals NHS Trust, Inflammatory Bowel Disease Unit, Hull, UK, 5University of Hull and York, Hull York Medical School, Hull, UK, 6University of Turin, Surgical Sciences, Turin, Italy, 7University Hospital Zurich, Medicine, Zurich, Switzerland, 8University of Ioannina School of Medical Sciences, Gastroenterology, Ioannina, Greece, 9University Hospital Galway, Gastroenterology, Galway, Ireland, 10Grand Hopital de Charleroi, Gastroenterology and Hepatology, Charleroi, Belgium, 11University Hospital Saint-Luc, Gastroenterology and Hepatology, Bruxelles, Belgium, 12Hospital de Clinicas de Porto Alegre, Gastroenterology, Rio Grande do Sul, Brazil, 13University Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy, 14University of Parma, Gastroenterology and Endoscopy Unit, Parma, Italy, 15Sacro Cuore Don Calabria of Negrar, Negrar, Italy, 16Hannover Medical School, Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, 17Sheba Medical Centre, Gastroenterology, Ramat Gan, Israel

P376: Effects of IV vedolizumab on health-related quality of life and work productivity in patients with Crohn’s disease: results from the Phase 3b VERSIFY trial

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Danese1, S. Adsul*2, D. Lindner2, S. Jones3, H. Patel4, J-F. Colombel5

1Humanitas University, Milan, Italy, 2Takeda Pharmaceuticals International AG, Zurich, Switzerland, 3Takeda Development Centre Europe Ltd., London, UK, 4Takeda Pharmaceuticals International, Deerfield, USA, 5Icahn School of Medicine at Mount Sinai, New York, USA

P377: Clinical strategies based on patient-reported outcomes and physicians’ preferences to monitor biological therapy in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Risager Christensen*1, C. Steenholdt1, S. Buhl Næss-Schmidt1, J. Brynskov1, M. A. Ainsworth1,2

1Herlev and Gentofte Hospital, Gastroentrology, Copenhagen, Denmark, 2Odense University Hospital, Gastroentrology, Odense, Denmark

P378: Changes in Simplified Endoscopic Score for Crohn’s disease (SES-CD) during a 16-week induction treatment with upadacitinib: analysis of the randomised controlled CELEST study

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Feagan*1, W. Sandborn2, S. Schreiber3, B. Huang4, G. Alperovich4, A. Pangan4, A. Lacerda4, G. D’Haens5

1Western University, London, Ontario, Canada, 2University of California San Diego, La Jolla, CA, USA, 3University Hospital Schleswig-Holstein, Kiel, Germany, 4AbbVie Inc., North Chicago, IL, USA, 5Amsterdam University Medical Centers, Amsterdam, The Netherlands

P379: Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naïve patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Latremouille-Viau1, R. Burne1, S. Shi1, S. Adsul2, H. Patel*2

1Analysis Group, Montreal, Canada, 2Takeda Pharmaceutical Company, Ltd., Deerfield, IL, USA

P380: A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Danese*1, A. Hart2, A. Dignass3, G. Fiorino1, E. Louis4, G. D'Haens5, I. Dotan6,7, G. Rogler8, K. Paridaens9, L. Peyrin-Biroulet10

1IBD Center Humanitas Clinical and Research Centre, Rozzano, Milan, Italy, 2St Mark's Hospital, Harrow, UK, 3Department of Medicine I, Agaplesion Markus Hospital, Goethe-University, Frankfurt am Main, Germany, 4CHU de Liège, Liège, Belgium, 5Academic Medical Centre, Amsterdam, The Netherlands, 6Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel, 7The Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel, 8Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, 9Global Medical Affairs Gastroenterology, Ferring Pharmaceuticals Center S.A, Saint-Prex, Switzerland, 10Department of Gastroenterology and Inserm u954, Lorraine University, Nancy, France

P381: Infliximab induction regimes in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Sebastian*1,2, S. Myers1, N. Syed1, K. Argyriou3, G. Martin4, L. Los5, J. Fiske6, R. Ranjan7, B. Cooper8, N. Patel9, V. Goodoory10, F. Shaikh10, H. L. Ching11, N. Jayasooriya12, J. Brooks13, A. Dhar7, A. H. Shenoy8, J. Limdy6, J. Butterworth5, P. B. Allen4, S. Samuel3, G. Moran3, R. Shenderey10, G. Parkes12, A. Lobo11, S. Subramanian9, T. Raine14

1IBD Unit, Hull & East Yorkshire Hospitals NHS Trust, Hull, UK, 2Hull York Medical School, University of Hull and York, Hull, UK, 3Nottingham University Hospitals NHS Trust, Nottingham, UK, 4South Eastern Trust, Belfast, UK, 5Royal Shrewsbury Hospitals NHS Trust, Shrewsbury, UK, 6Pennine Acute Hospitals NHS Trust, Manchester, UK, 7County Durham and Darlington NHS Foundation Trust, Durham, UK, 8Colchester Hospital University Foundation Trust, Colchester, UK, 9Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK, 10Airedale NHS Foundation Trust, Airedale, UK, 11Sheffield Teaching Hospitals NHS Trust, Sheffield, UK, 12Royal London Hospital, Barts Health NHS Trust, London, UK, 13Addenbrookes Hospital, University of Cambridge, Cambridge, UK, 14Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

P382: Combination therapy with TNF-inhibitors and immunomodulators are associated with shorter duration to first serious infection: the DEVELOP experience

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Escher*1, B. Gold2, J. Izanec3, C. Busse4, Y. Wang5, S. Cucchiara6

1Erasmus MC-Sophia Children’s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands, 2GI Care for Kids and Emory University Hospital, Atlanta, USA, 3Janssen Scientific Affairs, LLC, Horsham, USA, 4Janssen Pharmaceuticals, Horsham, USA, 5Janssen Research and Development, LLC, Spring House, USA, 6Sapienza University of Rome, Rome, Italy

P383: One-year experience with ustekinumab in therapy-refractory or -intolerant patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Ochsenkühn1, C. Tillack2, F. Schnitzler3, D. Szokodi2, S. Janelidze2

1Isarklinikum München, Gastroenterology, Munich, Germany, 2IBD center Munich, Munich, Germany, 3Gastroklinik Pasing, Munich, Germany

P384: High incidence of hyperglycaemia in steroid treated hospitalised inflammatory bowel disease (IBD) patients and its risk factors identified by machine learning methods

ECCO '19 Copenhagen

Year: 2019
Authors:

M. McDonnell*1, R. Harris1, T. Mills1, L. Downey1, S. Dharmasiri1, R. Felwick1, F. Borca2, H. Phan2, F. Cummings1,3, M. Gwiggner1

1University Hospital Southampton, Gastroenterology, Southampton, UK, 2University of Southampton, NIHR Southampton Biomedical Research Centre, Southampton, UK, 3University of Southampton, Faculty of Medicine, Southampton, UK

P385: TREM1, the first anti-TNF specific biomarker guiding therapeutic decision

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Verstockt*1,2, S. Verstockt3, J. Dehairs4, V. Ballet1, H. Blevi2, W-J. Wollants2, C. Breynaert5, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium, 4Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium, 5KU Leuven, Department of Microbiology and Immunology, Laboratory of Clinical Immunology, Leuven, Belgium

P386: Association of Infliximab trough levels and perianal disease activity in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Simões*1, S. Fernandes1, S. Bernardo1, A. R. Gonçalves1, C. Baldaia1, A. Valente1, P. Moura Santos1, L. Correia1, R. Tato Marinho1

1Hospital de Santa Maria, Gastroenterology, Lisbon, Portugal

P387: Efficacy of combination therapy of fresh faecal microbiota transplantation and triple-antibiotic therapy for ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Ishikawa*1, M. Takahashi1, K. Okahara1, S. Ito1, K. Haga1, T. Shibuya1, T. Osada2, A. Nagahara1

1Juntendo University, Gastroenterology, Tokyo, Japan, 2Juntendo Urayasu Hospital, Gastroenterology, Urayasu, Japan

P388: Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme

ECCO '19 Copenhagen

Year: 2019
Authors:

F. A. Farraye1, T. Qazi1, P. G. Kotze*2, G. T. Moore3,4, C. Kayhan5, R. Mundayat5, E. Maller5, C. Su5, A. Soonasra5

1Boston Medical Center, Section of Gastroenterology, Boston University School of Medicine, Boston, MA, USA, 2Cajuru University Hospital, Pontifical Catholic University of Paraná (PUCPR), IBD Outpatient Clinics, Colorectal Surgery Unit, Curitiba, Brazil, 3Monash Health, Department of Gastroenterology, Melbourne, VIC, Australia, 4Monash University, School of Clinical Sciences at Monash Health, Melbourne, VIC, Australia, 5Pfizer Inc., Collegeville, PA, USA

P389: Systematic review and meta-analysis of risk factors for recurrent primary sclerosing cholangitis

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Steenstraten1, K. Sebib Korkmaz1, P. Trivedi3,4,5,6, A. Inderson1, B. van Hoek1, M. Rodriguez Girondo7, J. Maljaars*1

1LUMC, Gastroenterology-Hepatology, Leiden, The Netherlands, 3National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Birmingham, UK, 4University Hospitals Birmingham, Birmingham, UK, 5University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, UK, 6University of Birmingham, Institute of Applied Health Research, Birmingham, UK, 7LUMC, Department of Biomedical Data Sciences, Leiden, The Netherlands

P390: The impact of anti-TNF therapy in adjuvant setting on postoperative recurrence patterns over decades in complicated Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

F. Colombo*1, A. Frontali2, L. Conti1, C. Baldi1, S. Ardizzone3, G. Maconi3, F. Corsi4, D. Foschi1, G. M. Sampietro1

1Luigi Sacco University Hospital, General Surgery, Milano, Italy, 2Hôpiteau de Paris (AP-HP), Beaujon Hospital, University Denis Diderot, Department of Colorectal Surgery, Pôle des Maladies de l'Appareil Digestif (PMAD),, Paris, France, 3Luigi Sacco University Hospital, Gastroenterology, Milano, Italy, 4ICS Maugeri, General Surgery Department, Pavia, Italy

P391: Are cut-off ranges of Infliximab serum levels in Crohn’s disease always the same in clinical practice?

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Valdes Delgado1, M. Guerra Veloz*1, M. Belvis Jimenez1, B. Maldonado Pérez1, L. Castro Laria1, A. Benítez Roldán1, R. Perea Amarillo1, V. Merino Bohorquez2, M. A. Calleja Hernandez2, T. Ortiz3, A. Caunedo Álvarez1, A. Vilches Arenas4, A. Saez Diaz5, F. Argüelles-Arias1

1Virgen Macarena Hospital, Gastroenterology, Seville, Spain, 2Virgen Macarena Hospital, Pharmacy Unit, Seville, Spain, 3University of Seville, Seville, Spain, 4Virgen Macarena Hospital, Preventive Medicine and Public Health, Seville, Spain, 5Virgen Macarena Hospital, Statistics, Seville, Spain